临床视角：抗体药物偶联物治疗 HER2 阳性乳腺癌。
Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.
机构信息
Department of Internal Medicine, School of Medicine, Kerman University of Medical Sciences, Kerman 7616913355, Iran.
Student Research Committee, Larestan University of Medical Sciences, Larestan 7431895639, Iran.
出版信息
Mol Ther. 2023 Jul 5;31(7):1874-1903. doi: 10.1016/j.ymthe.2023.03.019. Epub 2023 Mar 22.
Antibody-drug conjugates (ADCs) are a promising class of cancer biopharmaceuticals that exploit the specificity of a monoclonal antibody (mAb) to selectively deliver highly cytotoxic small molecules to targeted cancer cells, leading to an enhanced therapeutic index through increased antitumor activity and decreased off-target toxicity. ADCs hold great promise for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after the approval and tremendous success of trastuzumab emtansine and trastuzumab deruxtecan, representing a turning point in both HER2-positive breast cancer treatment and ADC technology. Additionally and importantly, a total of 29 ADC candidates are now being investigated in different stages of clinical development for the treatment of HER2-positive breast cancer. The purpose of this review is to provide an insight into the ADC field in cancer treatment and present a comprehensive overview of ADCs approved or under clinical investigation for the treatment of HER2-positive breast cancer.
抗体药物偶联物（ADCs）是一类很有前途的癌症生物制药，利用单克隆抗体（mAb）的特异性，将高细胞毒性的小分子选择性递送到靶向癌细胞，从而通过增加抗肿瘤活性和降低脱靶毒性来提高治疗指数。在曲妥珠单抗-美坦新和曲妥珠单抗-德曲妥珠单抗获得批准并取得巨大成功后，ADCs 为治疗人表皮生长因子受体 2（HER2）阳性乳腺癌的患者带来了巨大的希望，这代表着 HER2 阳性乳腺癌治疗和 ADC 技术的一个转折点。此外，非常重要的是，目前共有 29 种 ADC 候选药物正在不同的临床开发阶段，用于治疗 HER2 阳性乳腺癌。本综述的目的是深入了解癌症治疗中的 ADC 领域，并全面概述已批准或正在临床研究中用于治疗 HER2 阳性乳腺癌的 ADC。
Zotero 插件